Ask your GP about weight-loss injections this month and you might notice something that wasn't there a year ago: your surgery now has a financial reason to say yes. Since April, practices in England have been able to earn payments worth up to £3,000 for prescribing Mounjaro (tirzepatide) to eligible patients, the first time a weight-loss drug has been written into the GP contract. It sounds like good news for the roughly two million people already paying for these jabs privately because the NHS route has been too slow, too patchy, or simply unavailable at their surgery. Whether it actually is good news depends on where you live, which conditions you have alongside your weight, and whether your practice decides to bother at all.
A £3,000 reason for practices to say yes
The change sits inside the 2026/27 GP contract, agreed between NHS England and the Department of Health and Social Care and rolled out from 1 April. Two new indicators were added to the Quality and Outcomes Framework (QOF), the scheme that pays practices for hitting specific clinical targets, backed by £25 million in ring-fenced funding. Practices are now rewarded for identifying patients living with obesity, offering evidence-based advice, and — where clinically appropriate — prescribing Mounjaro directly or referring patients into specialist NHS weight-management services. The average payment available per practice is around £3,000, though the actual sum depends on practice size and patient list. Health Secretary Wes Streeting framed it plainly at the announcement in February: weight-loss drugs can be a genuine turning point for people who need them, and access should depend on clinical need rather than the ability to pay privately. Wegovy sits outside this particular incentive, since it's still dispensed through specialist NHS weight-management services rather than issued directly by GPs, and practices instead receive roughly £1,000 a year for referring eligible patients into those services. And crucially, nothing in the new contract actually obliges a practice to prescribe Mounjaro — participation is voluntary, some GPs remain cautious about long-term safety monitoring, and a surgery can hit its QOF target simply by referring patients elsewhere without writing a single tirzepatide prescription itself.
What the QOF payment does and doesn't require
- Practices must record and identify patients who meet the obesity criteria — this alone unlocks part of the funding, regardless of what happens next
- Offering dietary and lifestyle advice counts towards the indicator, even before any drug is discussed
- Referral to NHS weight-management services also counts, so a practice can hit its target without prescribing tirzepatide itself
- There is no penalty for opting out entirely, which is exactly why coverage across England is so inconsistent
Who actually qualifies — and the goalposts keep moving
Eligibility has shifted twice in six months, and it's due to shift again. From April, GPs could prescribe to patients with a BMI of 40 or above who also had at least four weight-related health conditions, such as type 2 diabetes, hypertension, or obstructive sleep apnoea. From 23 June, that threshold widened: a BMI of 35 to 39.9 with four qualifying conditions now qualifies, as does a BMI of 40 or above with only three conditions. NHS England has signalled a further loosening for people with a BMI of 40 or more and just three conditions from March 2027, which suggests the direction of travel is toward broader access rather than tighter rationing. One detail that gets missed in most summaries: the BMI thresholds are lower — by 2.5 points — for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, reflecting the fact that these groups tend to develop weight-related health problems at a lower BMI than the standard scale assumes. If you fall into one of those groups and were told your BMI didn't quite meet the cut-off, it's worth asking your GP to check the criteria again rather than assuming you're excluded.
The NHS price hasn't moved. The private price has, by up to 170%.
Same drug, same country, wildly different bill depending on which door you walk through.
On the NHS, Mounjaro at its highest 15mg maintenance dose costs the health service roughly £122 a month per patient, and patients themselves pay only the standard prescription charge of £9.90 per item in England — or nothing at all if they qualify for one of the usual exemptions. That price was explicitly protected when Eli Lilly renegotiated its private list price with the UK government in August 2025. Private prices tell a completely different story. From 1 September 2025, Eli Lilly raised its UK list price for Mounjaro sharply — the 2.5mg starter dose went from £92 to £133 a month, and the 15mg maintenance dose jumped from £122 to £330, an increase of up to 170%. The move came as the US administration pressed pharmaceutical companies to raise prices abroad in exchange for lower US list prices, and Eli Lilly confirmed the increase was meant to bring UK pricing closer to what patients pay elsewhere in Europe. Some providers absorbed the shock better than others — Pharmacy2U, one of the UK's largest online pharmacies, froze its own patient prices rather than pass the full increase on immediately — but most private clinics and online pharmacies have raised their fees to reflect the new list price, meaning private patients are now typically paying anywhere from £140 to over £300 a month depending on dose and provider. That gap, between a £9.90 prescription charge and a £330 monthly private bill for the identical drug, is precisely what makes the GP contract change matter so much to people currently paying out of pocket.
Not every surgery is on board
Here's the catch nobody mentions in the press releases: having a national contract incentive doesn't mean every GP surgery in the country is actually using it. A British Medical Journal investigation published in January 2026 found that roughly one in five local areas in England still lacked a functioning NHS pathway for tirzepatide prescribing, months after national guidance said the drug should be available. Integrated Care Boards — the regional bodies responsible for commissioning services — were criticised for inconsistent implementation, with some areas running smooth referral routes and others offering patients almost nothing beyond a leaflet about diet and exercise. The QOF incentive works well in theory — unless your Integrated Care Board happens to be one of the fifth still without a working pathway, in which case a national contract change on paper means very little until local commissioning actually catches up with it.
That inconsistency is precisely why community pharmacy is being pulled into the picture as a second route rather than a replacement. An £85 million programme, co-funded by the government and Eli Lilly, is expected to launch around summer 2026, testing whether pharmacies and digital health platforms can deliver weight-management support alongside — or instead of — traditional GP pathways. Separately, the 2026/27 Community Pharmacy Contractual Framework is set to introduce independent prescribing rights in NHS community pharmacy from autumn 2026, meaning pharmacists themselves may eventually be able to prescribe directly rather than simply dispensing what a GP has already signed off. None of that is live yet, but it explains why your local pharmacist might soon know more about your options than your GP receptionist does.
Half of patients drop off within a year — and it's mostly about cost
None of this solves the biggest problem with weight-loss injections in the UK, which has nothing to do with eligibility criteria and everything to do with sticking with the treatment once it starts. Across the private and NHS markets combined, roughly half of patients on GLP-1 and dual-agonist weight-loss drugs stop taking them within twelve months, and cost is consistently cited as the main reason people quit rather than side effects or lack of results. That's a striking figure given how effective the drugs are while patients stay on them, and it's a strong argument for treating the NHS route as worth pursuing properly rather than defaulting to a private prescription because it feels faster. A £9.90 prescription charge is sustainable for a year or two of treatment in a way that £250 or £300 a month simply isn't for most households, and dropping off a GLP-1 drug abruptly is associated with regaining a significant share of the weight lost, which is its own argument for choosing the option you can actually afford to continue.
What to actually do if you're chasing NHS access
Don't assume your practice is participating just because the national contract allows it — ring up and ask directly whether Mounjaro prescribing is something they currently offer, and if not, whether they refer into a specialist weight-management service instead. That single phone call saves weeks of assuming you're eligible only to discover your surgery has quietly opted out of the QOF indicator this year. If your BMI and conditions genuinely meet the June 2026 criteria and your practice still isn't offering anything beyond generic advice, raise it through the practice's patient participation group or consider registering with a neighbouring surgery that does prescribe — you're not obliged to wait passively for your own GP to catch up with national policy. And if none of that works quickly enough and you're weighing up paying privately in the meantime, factor in the September price rise properly: budgeting for £330 a month at the top dose, not the £122 figure that's still floating around from before last autumn, will save you an unpleasant surprise on your first private prescription.